ATE461179T1 - Hemmer der akt aktivität - Google Patents
Hemmer der akt aktivitätInfo
- Publication number
- ATE461179T1 ATE461179T1 AT04750378T AT04750378T ATE461179T1 AT E461179 T1 ATE461179 T1 AT E461179T1 AT 04750378 T AT04750378 T AT 04750378T AT 04750378 T AT04750378 T AT 04750378T AT E461179 T1 ATE461179 T1 AT E461179T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- activity inhibitor
- act activity
- directed
- act
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46512403P | 2003-04-24 | 2003-04-24 | |
| PCT/US2004/012157 WO2004096129A2 (en) | 2003-04-24 | 2004-04-20 | Inhibitors of akt activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE461179T1 true ATE461179T1 (de) | 2010-04-15 |
Family
ID=33418187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04750378T ATE461179T1 (de) | 2003-04-24 | 2004-04-20 | Hemmer der akt aktivität |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7304063B2 (de) |
| EP (1) | EP1620411B1 (de) |
| JP (1) | JP4673300B2 (de) |
| CN (1) | CN100422158C (de) |
| AT (1) | ATE461179T1 (de) |
| AU (1) | AU2004233826B2 (de) |
| CA (1) | CA2522262A1 (de) |
| DE (1) | DE602004026047D1 (de) |
| WO (1) | WO2004096129A2 (de) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004096131A2 (en) * | 2003-04-24 | 2004-11-11 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2005061519A1 (en) | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| CN1942470A (zh) | 2004-04-09 | 2007-04-04 | 默克公司 | Akt活性抑制剂 |
| EP1737843B1 (de) | 2004-04-09 | 2011-02-23 | Merck Sharp & Dohme Corp. | Hemmer der akt aktivität |
| US7550598B2 (en) | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| AU2005290081B2 (en) * | 2004-08-23 | 2010-12-02 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| AU2006258124B8 (en) | 2005-06-10 | 2010-01-07 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1978964A4 (de) | 2006-01-24 | 2009-12-09 | Merck & Co Inc | Jak2-tyrosinkinase-hemmung |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| CA2670767A1 (en) * | 2006-12-06 | 2008-06-12 | Merck & Co., Inc. | Inhibitors of akt activity |
| AR064010A1 (es) * | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| AU2009255358A1 (en) * | 2008-06-03 | 2009-12-10 | Msd K.K. | Inhibitors of Akt activity |
| CA2726358A1 (en) * | 2008-06-03 | 2009-12-10 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| WO2010091306A1 (en) | 2009-02-05 | 2010-08-12 | Tokai Pharmaceuticals | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| EP2405756B1 (de) | 2009-03-12 | 2013-07-03 | Merck Sharp & Dohme Corp. | Hemmer der akt-aktivität |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | ｐ５３活性を増大する置換ピペリジン及びその使用 |
| EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
| AU2011285909B2 (en) | 2010-08-02 | 2016-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| EP2606134B1 (de) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina) |
| EP2613782B1 (de) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| EP3766975A1 (de) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina) |
| EP2654748B1 (de) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| CA2846272A1 (en) * | 2011-09-01 | 2013-03-07 | Novartis Ag | Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| EP3358013B1 (de) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| KR20150060724A (ko) | 2012-09-28 | 2015-06-03 | 머크 샤프 앤드 돔 코포레이션 | Erk 억제제인 신규 화합물 |
| DK2925888T3 (en) | 2012-11-28 | 2017-12-18 | Merck Sharp & Dohme | COMPOSITIONS AND METHODS OF CANCER TREATMENT |
| EP2935263B1 (de) | 2012-12-20 | 2018-12-05 | Merck Sharp & Dohme Corp. | Substituierte imidazopyridine als hdm2 inhibitoren |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| EP2968370A4 (de) | 2013-03-14 | 2016-09-21 | Univ Maryland | Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon |
| EP3033088A4 (de) | 2013-08-12 | 2017-03-08 | Tokai Pharmaceuticals, Inc. | Biomarker zur behandlung neoplastischer störungen mit androgen-anzielenden therapien |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| WO2018190719A2 (en) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| EP3833667B1 (de) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| EP3833668B1 (de) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| BR112021002267A8 (pt) | 2018-08-07 | 2023-02-07 | Merck Sharp & Dohme | Inibidores de prmt5 |
| CN114981298B (zh) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| CA3160153A1 (en) | 2019-12-17 | 2021-06-24 | Michelle Machacek | Prmt5 inhibitors |
| EP4076459B1 (de) | 2019-12-17 | 2026-04-29 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| EP4076460B1 (de) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs |
| BR112022012015A2 (pt) | 2019-12-17 | 2022-08-30 | Merck Sharp & Dohme Llc | Inibidores de prmt5 |
| BR112022022327A2 (pt) * | 2020-05-08 | 2023-01-03 | Georgiamune Llc | Moduladores de akt3 e métodos de uso dos mesmos |
| WO2026027944A1 (en) | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Anti-sirp alpha antibody formulations and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020127214A1 (en) * | 1995-11-16 | 2002-09-12 | Hemmings Brian Arthur | RAC-protein kinase as therapeutic agent or in diagnostics |
| CA2241080A1 (en) | 1995-12-20 | 1997-06-26 | Medical Research Council | Control of protein synthesis, and screening method for agents |
| JPH10265464A (ja) * | 1997-03-24 | 1998-10-06 | Sumitomo Pharmaceut Co Ltd | Ｌｄｌ受容体遺伝子発現増強剤 |
| US6060491A (en) * | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
| IL136458A0 (en) | 2000-05-30 | 2001-06-14 | Peptor Ltd | Protein kinase inhibitors |
| US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002083064A2 (en) * | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | A method of treating cancer |
| AU2002251266A1 (en) * | 2001-04-10 | 2002-10-28 | Merck Sharp And Dohme Limited | Inhibitors of akt activity |
| WO2002083140A1 (en) * | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
| ATE400274T1 (de) * | 2001-04-10 | 2008-07-15 | Merck & Co Inc | Hemmstoffe der akt aktivität |
| US20040116433A1 (en) * | 2002-04-08 | 2004-06-17 | Owens Andrew Pate | Inhibitors of akt activity |
| EP1423380B1 (de) * | 2001-08-03 | 2010-12-15 | Vertex Pharmaceuticals Incorporated | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
| US7273869B2 (en) * | 2002-04-08 | 2007-09-25 | Merck & Co., Inc. | Inhibitors of Akt activity |
| WO2003086394A1 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| US20060142178A1 (en) | 2002-04-08 | 2006-06-29 | Barnett Stanley F | Method of treating cancer |
| WO2003086403A1 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| WO2003086279A2 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| US7399764B2 (en) * | 2002-10-30 | 2008-07-15 | Merck & Co., Inc. | Inhibitors of Akt activity |
| US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
-
2004
- 2004-04-20 DE DE602004026047T patent/DE602004026047D1/de not_active Expired - Lifetime
- 2004-04-20 CA CA002522262A patent/CA2522262A1/en not_active Abandoned
- 2004-04-20 AT AT04750378T patent/ATE461179T1/de not_active IP Right Cessation
- 2004-04-20 JP JP2006513154A patent/JP4673300B2/ja not_active Expired - Fee Related
- 2004-04-20 US US10/554,186 patent/US7304063B2/en not_active Expired - Fee Related
- 2004-04-20 WO PCT/US2004/012157 patent/WO2004096129A2/en not_active Ceased
- 2004-04-20 AU AU2004233826A patent/AU2004233826B2/en not_active Ceased
- 2004-04-20 CN CNB2004800171175A patent/CN100422158C/zh not_active Expired - Fee Related
- 2004-04-20 EP EP04750378A patent/EP1620411B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1620411A4 (de) | 2007-10-24 |
| EP1620411B1 (de) | 2010-03-17 |
| JP4673300B2 (ja) | 2011-04-20 |
| WO2004096129A3 (en) | 2005-01-20 |
| WO2004096129A2 (en) | 2004-11-11 |
| US7304063B2 (en) | 2007-12-04 |
| AU2004233826A1 (en) | 2004-11-11 |
| DE602004026047D1 (de) | 2010-04-29 |
| AU2004233826B2 (en) | 2009-08-13 |
| EP1620411A2 (de) | 2006-02-01 |
| CA2522262A1 (en) | 2004-11-11 |
| CN100422158C (zh) | 2008-10-01 |
| JP2006524253A (ja) | 2006-10-26 |
| US20070082906A1 (en) | 2007-04-12 |
| CN1809540A (zh) | 2006-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004026047D1 (de) | Hemmer der akt aktivität | |
| ATE446752T1 (de) | Hemmer der akt aktivität | |
| ATE512957T1 (de) | Hemmer der akt aktivität | |
| ATE503483T1 (de) | Hemmer der akt aktivität | |
| ATE499364T1 (de) | Hemmer der akt aktivität | |
| ATE400274T1 (de) | Hemmstoffe der akt aktivität | |
| WO2004096130A3 (en) | Inhibitors of akt activity | |
| WO2006036395A3 (en) | Inhibitors of akt activity | |
| WO2003086279A3 (en) | Inhibitors of akt activity | |
| CA2480800A1 (en) | Inhibitors of akt activity | |
| MXPA05013349A (es) | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. | |
| IL178675A0 (en) | Monocyclic heterocycles as kinase inhibitors | |
| ATE346070T1 (de) | Purinderivate als kinaseinhibitoren | |
| MXPA03010961A (es) | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. | |
| MXPA05013076A (es) | Compuestos de isoindolina-1-ona como inhibidores de cinasa. | |
| DK1648905T3 (da) | Inhibitorer for thienopyridin- og furopyridinkinase | |
| HRP20050533A2 (en) | Aminoindazole derivatives and use thereof as kinase inhibitors | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| MXPA05009151A (es) | Inhibidores de cinasa heterociclica. | |
| UA85087C2 (en) | Monocyclic heterocycles as kinase inhibitors | |
| TW200740812A (en) | 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
| ATE507218T1 (de) | Benzodiazepin-derivate als rock-kinasen hemmer | |
| ATE527264T1 (de) | Kondensierte heterozyklische verbindungen als hemmer von proteinkinasen | |
| TW200602023A (en) | Monocyclic heterocycles as kinase inhibitors | |
| ATE540951T1 (de) | Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |